title: IGF-1 antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength.
abstract: Botulinum toxin type-A (Btx-A), a powerful therapeutic tool in various medical specialties, requires repeated injections to maintain its effect. Therefore, novel methods to prolong the effective duration time of Btx-A are highly needed. Rats were assigned to three major groups: control group (n = 30), Btx-A group (n = 30), and IGF-1 Ab groups. IGF-1 Ab groups were composed by sub-groups A1-A5 (each has 25 rats) for the subsequent IGF-1Ab dose-effect study. Muscle strength was determined by a survey system for rat lower limbs nerve and muscle function. Muscle-specific receptor tyrosine kinase (MuSK), Insulin-like growth factor binding protein-5 (IGFBP5), and growth-associated protein, 43-kDa (GAP43) were determined by real-time polymerase chain reactions (PCRs) and Western blot. We found that Btx-A decreased the muscle strength, with a paralysis maintained for 70 days. IGF-1Ab prolonged the effective duration time of Btx-A. Real-time PCRs and Western blot showed that IGF-1Ab delayed the increase of MuSK and IGFBP5 after Btx-A injection, without affecting GAP43. These results indicate that IGF-1Ab might prolong the effective duration time of Btx-A on muscle strength through delaying the increase of MuSK. It would be interesting to determine whether IGF-1Ab can be used as an auxiliary measure to the Btx-A treatment in the future.
authors.affiliation: Department of Neurology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China. lingjingjin@hotmail.com.
authors.forename: Lingjing
authors.initials: L
authors.lastname: Jin
authors.forename: Lizhen
authors.initials: L
authors.lastname: Pan
authors.forename: Wuchao
authors.initials: W
authors.lastname: Liu
authors.forename: Yan
authors.initials: Y
authors.lastname: Guo
authors.forename: Yuguo
authors.initials: Y
authors.lastname: Zheng
authors.forename: Qiang
authors.initials: Q
authors.lastname: Guan
authors.forename: Zhiyu
authors.initials: Z
authors.lastname: Nie
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D001905:Botulinum Toxins / Q000494:pharmacology*; D019922:GAP-43 Protein / Q000378:metabolism; D007267:Injections; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000276:immunology*; D008297:Male; D053580:Muscle Strength / Q000187:drug effects*; D010243:Paralysis / Q000503:physiopathology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D017207:Rats, Sprague-Dawley; D011950:Receptors, Cholinergic / Q000378:metabolism; D013997:Time Factors
chemical_list: D000906:Antibodies; D019922:GAP-43 Protein; D018975:Insulin-Like Growth Factor Binding Protein 5; D012333:RNA, Messenger; D011950:Receptors, Cholinergic; D007334:Insulin-Like Growth Factor I; D001905:Botulinum Toxins